Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L26 pseudogene 30 (RPL26P30) is a processed pseudogene related to the ribosomal protein L26 gene, which normally encodes a structural component of the 60S large ribosomal subunit[2]. Pseudogenes like RPL26P30 do not produce functional proteins, and this gene does not encode a functional receptor, enzyme, or other therapeutic target. It is one of multiple dispersed pseudogenes found within the genome that arose from duplication or retrotransposition of the parent ribosomal protein gene[2]. There is no evidence for therapeutic targeting, disease association, or regulatory function reported for this pseudogene. RPL26P30 is not a coding gene nor a biological target, but a non-functional genomic sequence related to the ribosome[2]. Its parent gene, RPL26, encodes a protein that is a component of ribosomal subunit 60S, with an established role in protein synthesis[1][3]. Pseudogenes are not typically involved in disease, drug targeting, or biological functions unless specifically proven otherwise, which is not the case for RPL26P30.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L26 pseudogene 30 (RPL26P30).